PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood
Public support
Provider
Ministry of Education, Youth and Sports
Programme
—
Call for proposals
7E13061-2013
Main participants
Fakultní nemocnice Brno
Contest type
RP - Co-financing of EC programme
Contract ID
MSMT-42111/2013
Alternative language
Project name in Czech
PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood
Annotation in Czech
Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The goal of PanCareLIFE is that survivors of cancer diagnosed before age 25 should enjoy the same quality of life and opportunities as their peers who have not had cancer. Using observational studies and molecular genetic investigations PanCareLIFE will investigate late effects that impact fertility and hearing impairment (ototoxicity), and will assess health-related quality of life. Information from PanCareLIFE’s studies will be incorporated into new guidelines for fertility preservation. As the number of survivors with late effects in any one country is small, large cohorts are required for accurate estimation of risk. PanCareLIFE has assembled a team of prominent investigators from 8 European countries who will contribute in total over 12,000 well-characterised research subjects to identify risk factors, both genetic and non-genetic, linked to decrements in fertility and ototoxicity. Quality-of-life studies will evaluate the impact of fertility and ototoxicity. PanCareLIFE will advance the state-of-the-art in survivorship studies by evaluation of large cohorts with observational and genetic tools that will provide better knowledge of individual risk factors. Survivors can then be stratified into groups benefitting from personalized, evidence-based, care; future patients may expect effective therapies to have less severe side effects, and plans for a seamless transition to long-term follow-up care can be made. These approaches will result in better quality of life for survivors of cancer diagnosed at a young age.
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
FD - Oncology and haematology
CEP - secondary branch
FK - Gynaecology and obstetrics
CEP - another secondary branch
FF - ENT (ie. ear, nose, throat), ophthalmology, dentistry
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
30204 - Oncology<br>30205 - Hematology<br>30206 - Otorhinolaryngology<br>30207 - Ophthalmology<br>30208 - Dentistry, oral surgery and medicine<br>30214 - Obstetrics and gynaecology
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider.
Solution timeline
Realization period - beginning
Nov 1, 2013
Realization period - end
Oct 31, 2018
Project status
U - Finished project
Latest support payment
Feb 14, 2018
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP19-MSM-7E-U/01:1
Data delivery date
Jun 18, 2019
Finance
Total approved costs
1,596 thou. CZK
Public financial support
1,596 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK